Subscribe
20 June 2013Big Pharma

European Commission targets alleged ‘pay-for-delay’ with pharma fines

The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
European Commission commits €100bn for research and innovation
8 June 2018   The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.
Americas
US Supreme Court backs ‘rule-of-reason’ for pay-for-delay
17 June 2013   A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.
Americas
FTC critical of pay-for-delay in annual report
24 April 2013   The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Big Pharma
European Commission commits €100bn for research and innovation
8 June 2018   The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.
Americas
US Supreme Court backs ‘rule-of-reason’ for pay-for-delay
17 June 2013   A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.
Americas
FTC critical of pay-for-delay in annual report
24 April 2013   The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.

More on this story

Big Pharma
European Commission commits €100bn for research and innovation
8 June 2018   The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.
Americas
US Supreme Court backs ‘rule-of-reason’ for pay-for-delay
17 June 2013   A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.
Americas
FTC critical of pay-for-delay in annual report
24 April 2013   The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.

More features

Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders
Former PTAB judge joins Sterne Kessler
GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space